Loading
institutionsInstitution
University Cancer Center Mainz (UCT Mainz) / Universitätsmedizin Mainz
The university medical centre where Uğur Şahin and Özlem Türeci built the science behind BioNTech and personalised mRNA cancer vaccines.
Also called: Universitätsmedizin der Johannes Gutenberg-Universität MainzTRONHI-TRON Mainz
Overview
Universitätsmedizin Mainz is the home institution of Uğur Şahin and Özlem Türeci, who founded BioNTech in Mainz in 2008 and the translational institute TRON in 2010 to pursue individualised neoantigen mRNA vaccines, the concept later tested as autogene cevumeran with Genentech. The Helmholtz Institute for Translational Oncology (HI-TRON), a DKFZ partnership, and the UCT Mainz make the site a German Cancer Aid Oncology Center of Excellence and DKTK partner. Clinical strengths include haematology, dermato-oncology (a large melanoma trial site for BioNTech's programmes), neuro-oncology and the Mainz Research Center for Immunotherapy (FZI). The city has become a hub for mRNA and immunotherapy companies around the university.
Location
Mainz, DE
Type
university · Johannes Gutenberg-Universität Mainz
Website
Newsweek 2026 oncology rank
Not in top 300 listing used
OnCo score
#249 · 26 points (0 Newsweek + 0 NCI + 26 from 13 linked objects) · ranking
Research output
From OpenAlex, oncology works in the last five years (2022 to 2026, current year in progress); counted on 2026-09-17.
Matched to University Medical Center of the Johannes Gutenberg University Mainz, including child institutions. 483 works · 5,527 citations · 79% open access · 12% clinical trials · 2% reviews.
Oncology works per year
1002022
862023
1052024
1142025
782026
Most works
- Marcus Schmidt26 works
- Annette Hasenburg24 works
- Stephan Grabbe24 works
- Susanne Singer22 works
- Carmen Loquai22 works
- Dirk Schadendorf20 works
- Ralf Gutzmer16 works
- Friedegund Meier16 works
- Peter Mohr16 works
- Selma Ugurel16 works
Most cited
- Individualised mRNA cancer vaccines (TRON, BioNTech)
- HI-TRON Mainz
- Research Center for Immunotherapy
- Melanoma
- Haematology
Thomas Kindler
Director
HaematologyAcute leukaemiaMedical oncology
Haematologist-oncologist who directs the University Cancer Center Mainz at Universitätsmedizin Mainz.
Uğur Şahin
Professor of Translational Oncology, University Medical Center Mainz; Co-founder and CEO, BioNTech
mRNA cancer vaccinesNeoantigen immunotherapyTranslational oncology
Immunologist who built individualised mRNA neoantigen vaccines for cancer, the platform later used for COVID-19.
Similar pages
- IdeaPersonalised vaccines given only when the blood test turns positive
Shares Autogene cevumeran, BioNTech, Neoantigen, Personalised neoantigen (mRNA) vaccines.
- Key paperRojas 2023: a personalised mRNA vaccine trained T cells against each patient's pancreatic cancer, and those who responded stayed cancer-free longer
Shares Uğur Şahin, Autogene cevumeran, BioNTech, Neoantigen.
- IdeaPersonalised cancer vaccines at commodity cost through fully automated manufacturing
Shares Autogene cevumeran, BioNTech, Neoantigen, Personalised neoantigen (mRNA) vaccines.
- Key paperRNA neoantigen vaccines prime long-lived CD8+ T cells in pancreatic cancer
Shares Uğur Şahin, Autogene cevumeran, BioNTech, Neoantigen.
- TrialAutogene cevumeran phase 1 in resected pancreatic cancer (Memorial Sloan Kettering)
Shares Autogene cevumeran, BioNTech, Personalised neoantigen (mRNA) vaccines, Roche / Genentech.
- PairingPersonalised neoantigen vaccine + PD-1 blockade
Shares Autogene cevumeran, Personalised neoantigen (mRNA) vaccines, Melanoma, Pancreatic ductal adenocarcinoma.
- InstitutionComprehensive Cancer Center Tübingen-Stuttgart
Shares German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Neoantigen, Personalised neoantigen (mRNA) vaccines.
- TrialA Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX Versus mFOLFIRINOX Alone in Participants With Resected PDAC
Shares Autogene cevumeran, BioNTech, Personalised neoantigen (mRNA) vaccines, Pancreatic ductal adenocarcinoma.
cancers
fronts
technologies
drugs
Phase 2Personalised mRNA neoantigen vaccine